Absci shares spike 30% in IPO debut, valuing Washington state biotech company at nearly $2B
Just over a year after going public, Absci stocks are continuing to grow. The Vancouver, Washington based company now is valued at almost $2 billion.
Sean McClain, CEO of Absci started the company in 2011 and since has led the company through partnerships with several pharmaceutical companies, as well as recent acquisitions of both Totient and Denovium.
“They are a young company that in my mind has done everything right, in terms of its development,” said Dr. Leslie Alexandre, CEO of Life Science Washington. “For being relatively young in the business, he [Sean McClain] has performed the way you would expect of a more seasoned mature, life sciences CEO.”